Hideyuki Sawada

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Development of environment-responsive self-propelling robots with shape-preserving exoskeletons for directed interfacial motion.

Development of environment-responsive self-propelling robots with shape-preserving exoskeletons for directed interfacial motion.

Journal: RSC advances
Published: May 09, 2026

Hallucinations and cognitive impairment are associated with blood pressure fluctuations in Parkinson's disease.

Hallucinations and cognitive impairment are associated with blood pressure fluctuations in Parkinson's disease.

Journal: BMJ neurology open
Published: December 03, 2025

Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody-associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis, and seizure episodes.

Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody-associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis, and seizure episodes.

Journal: Frontiers in immunology
Published: December 25, 2024

Cortical involvement of lateral trunk flexion and verticality misperception in Parkinson's disease.

Cortical involvement of lateral trunk flexion and verticality misperception in Parkinson's disease.

Journal: Brain communications
Published: December 18, 2023

Analysis of different self-propulsion types of oil droplets based on electrostatic interaction effects.

Analysis of different self-propulsion types of oil droplets based on electrostatic interaction effects.

Journal: RSC advances
Published: March 31, 2022

Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.

Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.

Journal: Multiple sclerosis and related disorders
Published: November 30, 2021

Older-onset levodopa-responsive parkinsonism with normal DAT-SPECT and pterin hypometabolism.

Older-onset levodopa-responsive parkinsonism with normal DAT-SPECT and pterin hypometabolism.

Journal: BMJ case reports
Published: May 08, 2021

Early-start vs delayed-start donepezil against cognitive decline in Parkinson disease: a randomized clinical trial.

Early-start vs delayed-start donepezil against cognitive decline in Parkinson disease: a randomized clinical trial.

Journal: Expert opinion on pharmacotherapy
Published: September 02, 2020

Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply.

Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply.

Journal: The Lancet. Neurology
Published: June 27, 2020

Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder - Authors' reply.

Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder - Authors' reply.

Journal: The Lancet. Neurology
Published: May 18, 2020

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

Journal: The Lancet. Neurology
Published: November 18, 2019

Considerations for pharmacotherapy use in patients with amyotrophic lateral sclerosis: the earlier it starts, the better the results.

Considerations for pharmacotherapy use in patients with amyotrophic lateral sclerosis: the earlier it starts, the better the results.

Journal: Expert opinion on pharmacotherapy
Published: July 02, 2019
Showing 1-12 of 40

Last Updated: 09/26/2026